Global mRNA Vaccines & Therapeutics Expenses Market Average Growth Rate Of 17.52%
Wednesday, 31 Oct, 2018
mRNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of mRNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
Since the product still in development stage, so companies rely mainly on investment or cooperation to obtain funding to continue research and development.
The research of mRNA Vaccines & Therapeutics to treat infectious disease, cancer and others. The expenses on infectious disease is the most, with the market share of 46% in 2017
In the last several years, global expenses market of mRNA Vaccines & Therapeutics developed rapidly, with an average growth rate of 17.52%.
According to our prediction, the global revenue of mRNA Vaccines & Therapeutics in 2020 will reach 115 M USD; the global revenue of mRNA Vaccines & Therapeutics in 2030 will reach 920 M USD.
At present, global expenses concentrate in North America and Europe, North America takes 69% market share and Europe takes 28% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in mRNA Vaccines & Therapeutics) companies are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics. The five companies occupy about 90% of the market share.